Warburg Pincus, private equity firm, received $4.5 billion in the acquisition deal. The other $4.2 billion of Valeant’s payment was used to cover Bausch + Lomb’s outstanding debt.
Valeant’s acquisition is a step in the company’s efforts to expand in the ophthalmology market.
More Articles on Ophthalmology:
8 Recent Eye Surgery Center Openings, Mergers & Acquisitions
FDA Approves Bausch + Lomb TRULIGN Astigmatism Correction Lens
Dr. Eva Liang Opens Center for Sight in Las Vegas
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
